Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Oral Nirmatrelvir-Ritonavir as Postexposure Prophylaxis for Covid-19.
Hammond J, Yunis C, Fountaine RJ, Luscan G, Burr AM, Zhang W, Wisemandle W, Soares H, Baniecki ML, Hendrick VM, Kalfov V, Pypstra R, Rusnak JM. Hammond J, et al. Among authors: rusnak jm. N Engl J Med. 2024 Jul 18;391(3):224-234. doi: 10.1056/NEJMoa2309002. N Engl J Med. 2024. PMID: 39018532 Free PMC article. Clinical Trial.
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.
Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, Baniecki M, Hendrick VM, Damle B, Simón-Campos A, Pypstra R, Rusnak JM; EPIC-HR Investigators. Hammond J, et al. Among authors: rusnak jm. N Engl J Med. 2022 Apr 14;386(15):1397-1408. doi: 10.1056/NEJMoa2118542. Epub 2022 Feb 16. N Engl J Med. 2022. PMID: 35172054 Free PMC article. Clinical Trial.
Nirmatrelvir-Ritonavir and Viral Load Rebound in Covid-19.
Anderson AS, Caubel P, Rusnak JM; EPIC-HR Trial Investigators. Anderson AS, et al. Among authors: rusnak jm. N Engl J Med. 2022 Sep 15;387(11):1047-1049. doi: 10.1056/NEJMc2205944. Epub 2022 Sep 7. N Engl J Med. 2022. PMID: 36069818 Free PMC article. No abstract available.
Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19.
Hammond J, Fountaine RJ, Yunis C, Fleishaker D, Almas M, Bao W, Wisemandle W, Baniecki ML, Hendrick VM, Kalfov V, Simón-Campos JA, Pypstra R, Rusnak JM. Hammond J, et al. Among authors: rusnak jm. N Engl J Med. 2024 Apr 4;390(13):1186-1195. doi: 10.1056/NEJMoa2309003. N Engl J Med. 2024. PMID: 38598573 Free PMC article. Clinical Trial.
Alleviation of COVID-19 Symptoms and Reduction in Healthcare Utilization Among High-Risk Patients Treated With Nirmatrelvir/Ritonavir (NMV/R): A phase 3 randomized trial.
Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, Ansari W, Harrington MA, Simón-Campos A, Chew KW, Pypstra R, Rusnak JM. Hammond J, et al. Among authors: rusnak jm. Clin Infect Dis. 2024 Nov 11:ciae551. doi: 10.1093/cid/ciae551. Online ahead of print. Clin Infect Dis. 2024. PMID: 39523543
Successful Treatment of Prolonged, Severe Coronavirus Disease 2019 Lower Respiratory Tract Disease in a B cell Acute Lymphoblastic Leukemia Patient With an Extended Course of Remdesivir and Nirmatrelvir/Ritonavir.
Ford ES, Simmons W, Karmarkar EN, Yoke LH, Braimah AB, Orozco JJ, Ghiuzeli CM, Barnhill S, Sack CL, Benditt JO, Roychoudhury P, Greninger AL, Shapiro AE, Hammond JL, Rusnak JM, Dolsten M, Boeckh M, Liu C, Cheng GS, Corey L. Ford ES, et al. Among authors: rusnak jm. Clin Infect Dis. 2023 Mar 4;76(5):926-929. doi: 10.1093/cid/ciac868. Clin Infect Dis. 2023. PMID: 36326680 Free PMC article.
Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial.
Clarke DK, Xu R, Matassov D, Latham TE, Ota-Setlik A, Gerardi CS, Luckay A, Witko SE, Hermida L, Higgins T, Tremblay M, Sciotto-Brown S, Chen T, Egan MA, Rusnak JM, Ward LA, Eldridge JH. Clarke DK, et al. Among authors: rusnak jm. Lancet Infect Dis. 2020 Apr;20(4):455-466. doi: 10.1016/S1473-3099(19)30614-0. Epub 2020 Jan 14. Lancet Infect Dis. 2020. PMID: 31952923 Clinical Trial.
44 results